EcoDrugPlus

40s Ribosomal Protein S19

Ensembl ID : ENSSSAG00000003049
Gene Symbol: LOC106605681
4 Cross references
300 Possible Orthologues:

40s Ribosomal Protein S24

Ensembl ID : ENSSSAG00000074553
Gene Symbol: LOC106608423
5 Cross references
484 Possible Orthologues:

40s Ribosomal Protein S24

Ensembl ID : ENSSSAG00000053970
Gene Symbol: LOC106608423
5 Cross references
482 Possible Orthologues:

40s Ribosomal Protein S4-Like

Ensembl ID : ENSSSAG00000043043
Gene Symbol: LOC106578080
5 Cross references
488 Possible Orthologues:

40s Ribosomal Protein S5

Ensembl ID : ENSSSAG00000073777
Gene Symbol: LOC106570065
4 Cross references
258 Possible Orthologues:

40s Ribosomal Protein S9

Ensembl ID : ENSSSAG00000092128
Gene Symbol: LOC106605760
3 Cross references
232 Possible Orthologues:

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSSSAG00000078771
Gene Symbol: NT5E
4 Cross references
207 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSSSAG00000077901
Gene Symbol: HTR2B
4 Cross references
195 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 2c, G Protein-Coupled-Like 1

Ensembl ID : ENSSSAG00000056916
Gene Symbol: HTR2CL1
4 Cross references
194 Possible Orthologues:

5-Hydroxytryptamine (Serotonin) Receptor 5a, Genome Duplicate B

Ensembl ID : ENSSSAG00000068481
Gene Symbol: HTR5AB
4 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 1a-Beta-Like

Ensembl ID : ENSSSAG00000070900
Gene Symbol: LOC106567207
4 Cross references
132 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSSSAG00000078752
Gene Symbol: HTR1B
2 Cross references
176 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).